Clinical data | |
---|---|
Trade names | Evra, Ortho Evra |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a602006 |
Routes of administration |
Transdermal patch |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
|
|
Synonyms | Norelgestromine; Levonorgestrel 3-oxime; 17β-Deacetylnorgestimate; 17α-Ethynyl-18-methyl-19-nortestosterone 3-oxime; 17α-Ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H29NO2 |
Molar mass | 327.461 g/mol |
3D model (JSmol) | |
|
|
|
|
(what is this?) |
Norelgestromin, or norelgestromine, is a progestin which is used in the contraceptive patches Evra and Ortho Evra, in combination with the estrogen ethinylestradiol.
Norelgestromin is a progestogen. It is one of the active metabolites of norgestimate. Unlike many related progestins, norelgestromin has negligible androgenic activity.
Norelgestromin, also known as 17α-ethynyl-18-methyl-19-nortestosterone 3-oxime or as 17α-ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime, is a synthetic estrane steroid and a derivative of testosterone. It is a racemic mixture of E and Z isomers, which have approximately the same activity. Norelgestromin is more specifically a derivative of norethisterone (17α-ethynyl-19-nortestosterone) and is a member of the gonane (18-methylestrane) subgroup of the 19-nortestosterone family of progestins. It is the C3 oxime derivative of levonorgestrel and the C17β deacetyl derivative of norgestimate and is also known as levonorgestrel 3-oxime and as 17β-deacetylnorgestimate.
Norelgestromin was introduced in 2002.
Norelgestromin is the generic name of the drug and its INN, USAN, and BAN.